Claims for Patent: 5,885,974

Summary for Patent: 5,885,974

Title:	Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
Abstract:	Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically effective amount of a biocomplex comprising at least one bioactive agent from each of the three informational blocks of biological information transfer, each agent being present in an amount sufficient to correct the biological information transfer of the patient under treatment and resulting in the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent; together with a carrier therefor.
Inventor(s):	Danielov; Michael M. (Rego Park, NY)
Assignee:	Danielov; Michael M. (Rego Park, NY)
Application Number:	08/350,234
Patent Claims:	1. A composition for administration to a patient in conjunction with a bioactive agent, and which decreases the dosage of bioactive agent necessary, when administered to a patient with abnormal cell metabolism, to correct the abnormal cell metabolism and promote the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent, together with a biologically acceptable carrier therefor, wherein the composition comprises: a] adenosine-5-triphosphate; b] guanosine-5-triphosphate; c] phosphoinositedes containing: 1) 15-20% phosphotidyl inositol 4,5-diphosphate and phosphatidylinositol 4-monophosphate; 2) the remainder is a mixture of phosphatidylinositol and phosphotidylserine; d] Type I brain extract containing 10-20% phosphatidylinosilides, 50-60% phosphatidylserines, e] adenosine 3'5'-cyclic monophosphate sodium salt; f] guanosine 3'5'-cyclic monophosphate; g] d-myo-Inositol triphosphate; h] protein kinase; i] coenzyme A; j] .beta.-nicotinamide adenine dinucleotide; k] .beta.-nicotinamide adenine dinucleotide phosphate; and l] calmodulin. 2. composition according to claim 1 wherein the composition comprises by weight per 1 kg of formulated product: a] 1-50 mg adenosine-5-triphosphate; b] 1-30 mg guanosine-5-triphosphate; c] 10-100 .mu.g phosphoinositedes containing: 1) 15-20% phosphotidyl inositol 4,5-diphosphate and phosphatidylinositol 4-monophosphate; 2) the remainder is a mixture of phosphatidylinositol and phosphotidylserine; d] 0.5-10 mg Type 1 brain extract containing 10-20% phosphatidylinosilides, 50-60% phosphatidylserines; e] 1-10 mg adenosine 3'5'-cyclic monophosphate sodium salt; f] 0.1-5 mg guanosine 3'5'-cyclic monophosphate; g] 1-66 .mu.g d-myo-Inositol triphosphate; h] 1-25 mg .beta.-nicotiamide adenine dinucleotide phosphate; i] 0.01-0.25 protein kinase; j] 0.2-2 mg coenzyme A; k] 5-35 mg .beta.-nicotiamide adenine dinucleotide sodium salt; and l] 1-20 .mu.g calmodulin. 3. The composition according to claim 1 also comprising: adrenocorticotropic hormone; .beta.-lipotropin; .beta.-endorphin;somatotropin; follicle-stimulating hormone; luteinizing hormone; thyrotropic hormone; vasopressin; parathyroid hormone; thyrocalcitonin; angiotensin II; glucagon; vasoactive intestinal peptide; gastric inhibitory polypeptide; or insulin. 4. The composition according to claim 1 wherein the composition comprises by weight per 1 kg of formulated product: 2-120 ng adrenocorticotropic hormone; 1-10 .mu.g .beta.-lipotropin .beta.-endorphin; 1-10 .mu.g somatotropin; 0.01-1.0 .mu.g follicle-stimulating hormone; 0.05-0.5 .mu.g luteinizing hormone; 0.05-0.15 .mu.g thyrotropic hormone; 0.02-1.0 .mu.g vasopressin; 0.5-2.0 parathyroid hormone; 20-120 ng vasoactive intestinal peptide; and 0.5-5 .mu.g insulin. 5. The composition according to claim 1 also comprising: hydrocortisone; corticosterone-21-sulfate; progesterone; .beta.estradiol; estriol-3-sulfate sodium salt; cholecalciferol sulfate; epinephrine hydrochloride; arterenol hydrochloride; or aldosterone. 6. The composition according to claim 5 comprising by weight per 1 kg of formulated product: 25-250 .mu.g hydrocortisone; 1-30 .mu.g corticosterone-21-sulfate; 2-10 .mu.g progesterone; 50-500 ng .beta.-estradiol; 200-700 ng estriol-3-sulfate sodium salt; 200-700 ng epinephrine hydrochloride; 300-900 ng arterenol hydrochloride; or 10-600 ng .alpha.-aldosterone-21-hemisuccinate. 7. The composition according to claim 1 which further comprises a second bioactive agent comprising prostaglandin D.sub.2, prostaglandin E.sub.1, prostaglandin E.sub.2, prostaglandin F.sub.2.alpha. and prostaglandin I.sub.2. 8. The composition according to claim 7 comprising by weight per 1 kg of formulated product: 1-5 .mu.g prostaglandin D.sub.2, 1-5 .mu.g prostaglandin E.sub.1, 1-5 .mu.g prostaglandin E.sub.2, 0.5-3 .mu.g prostaglandin F.sub.2.alpha., or 1-5 .mu.g prostaglandin I.sub.2. 9. A composition for administration to a patient in conjunction with bioactive agents, and which decreases the dosage of bioactive agent necessary, when administered to a patient with abnormal cell metabolism, to correct the abnormal cell metabolism and promote the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent, together with a biologically acceptable carrier therefor, wherein the composition comprises: a] adenosine-5-triphosphate; b] guanosine-5-triphosphate; c] phosphoinositedes containing: 1) 15-20% phosphotidyl inositol 4,5-diphosphate and phosphatidylinositol 4-monophosphate; 2) the remainder is a mixture of phosphatidylinositol and phosphotidylserine; d] Type I brain extract containing 10-20% phosphatidylinosilides, 50-60% phosphatidylserines, and other brain lipids; e] adenosine 3'5'-cyclic monophosphate sodium salt; f] guanosine 3'5'-cyclic monophosphate; g] d-myo-Inositol triphosphate; h] protein kinase; i] coenzyme A; j] .beta.-nicotinamide adenine dinucleotide; k] .beta.-nicotinamide adenine dinucleotide phosphate; and l] calmodulin; wherein the composition further comprises a protein-peptide biocomplex bioactive agent comprising: adrenocorticotropic hormone; .beta.-lipotropin .beta.-endorphin; somatotropin; follicle-stimulating hormone; luteinizing hormone; thyrotropic hormone; vasopressin; parathyroid hormone; thyrocalcitonin; angiotensin II; glucagon; vasoactive intestinal peptide; gastric inhibitory polypeptide; insulin; or mixtures thereof; wherein the composition further comprises a second bioactive agent comprising: hydrocortisone; corticosterone-21-sulfate; progesterone; .beta.-estradiol; estriol-3-sulfate sodium salt; cholecalciferol sulfate epinephrine hydrochloride; arterenol hydrochloride; aldosterone and mixtures thereof; or wherein the composition further comprises a second bioactive agent comprising: prostaglandin D.sub.2, prostaglandin E.sub.1, prostaglandin E.sub.2, prostaglandin F.sub.2.alpha. prostaglandin I.sub.2, and mixtures thereof. 10. The method according to claim 1 wherein the composition is adapted for topical administration.

Details for Patent 5,885,974

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26